Incredible News about the Lupus Medication Benlysta! FDA makes priority review

Human Genome Sciences, Inc. (Nasdaq: HGSI) and GlaxoSmithKline PLC (GSK) today announced that the U.S. Food and Drug Administration (FDA) has granted a priority review designation to BENLYSTA® (belimumab) as a potential treatment for systemic lupus erythematosus (SLE). A priority review designation is granted to drugs that, if approved, offer major advances in treatment or provide a treatment where no adequate therapy exists. The FDA has assigned belimumab a Prescription Drug User Fee Act (PDUFA) target date of December 9, 2010.


http://www.hgsi.com/latest/human-genome-sciences-and-glaxosmithkline-announce-fda-priority-review-designation-for-benlysta-belimumab-as-a-potential-treatment-for-systemic-lupus-erythema.html


I will be first in line as soon as the FDA gives the thumbs up! I have been awaiting this now for well over 2 years, watching all of the clinical trials, and the positive results. I am so elated.... Rhia
Post a Comment